Order Online! Now! Get your $50 coupon for online order.Order Online! Now! Get your $50 coupon for online order.
Cancer Prevention Month: Get ACRO Health Gift Cards! Cancer Prevention Month: Get ACRO Health Gift Cards!
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
5e5 of anti-VEGF R2 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human VEGF R2 Protein, His Tag (Cat. No. VE2-HA224) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
5e5 of anti-VEGFR2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human VEGF R2, His Tag (Cat. No. KDR-HP227) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Loaded Biotinylated Mouse VEGF164, His,Avitag (Cat. No. VE4-M82Q3) on SA Biosensor, can bind Mouse VEGF R2 Protein, Mouse IgG2a Fc Tag (Cat. No. VE2-M5258) with an affinity constant of 1.33 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Mastocytosis, Systemic; Leukemia, Mast-Cell; Hematologic Neoplasms; Leukemia, Myeloid, Acute | Novartis Pharmaceuticals Corp | 2017-04-28 | Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
Sunitinib Malate | PHA-290940; SU-010398; SU-11248; GB-102; PNU-290940; SU-011248-L-malate salt; PNU-290940AD; PHA-290940AD; SCAI-003 | Approved | Pfizer Pharmaceuticals Ltd (China) | Sutent, 索坦 | United States | Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell | Cppi Cv | 2006-01-26 | Solid tumours; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leiomyosarcoma; Fibrosarcoma; Leukemia; Kidney Neoplasms; Teratoma; Head and Neck Neoplasms; HIV Infections; Intestinal Neoplasms; Ovarian Neoplasms; Ependymoma; Leukemia, Myeloid, Accelerated Phase; Fibromatosis, Aggressive; Liver Neoplasms; Lymphoma, T-Cell, Peripheral; Leukemia, Myelogenous, Chronic; Carcinoma, Renal Cell; Pheochromocytoma; Histiocytoma, Malignant Fibrous; Thoracic Neoplasms; Hemangioblastoma; Leukemia, Hairy Cell; Abdominal Neoplasms; Stomach Neoplasms; Carcinoma, Islet Cell; Polycythemia Vera; Esophageal Neoplasms; Carcinoma; Pelvic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Glioblastoma; Myelodysplastic Syndromes; Carcinoma, Papillary; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelomonocytic, Chronic; Neurofibromatoses; Pancreatic neuroendocrine tumors (pNET); Neoplasms; Adenoma, Islet Cell; Myeloproliferative Disorders; Pancreatic Neoplasms; Plasmacytoma; Carcinoma, Transitional Cell; Immunogl | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Carcinoma, Neuroendocrine; Thyroid Neoplasms | Exelixis Inc | 2012-11-29 | Carcinoma, Adenosquamous; Uterine Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Gliosarcoma; Bile Duct Neoplasms; Peritoneal Neoplasms; Astrocytoma; Colorectal Neoplasms; Brain Neoplasms; Endometrial Neoplasms; Osteosarcoma; Urethral Neoplasms; Adenocarcinoma, Clear Cell; Neuroblastoma; Neurofibroma, Plexiform; Cholangiocarcinoma; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Breast Neoplasms; Carcinoma, Endometrioid; Neoplasms, Germ Cell and Embryonal; Meningioma; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Cancer, Papillary; Neoplasm Metastasis; Paraganglioma; Carcinoma, Hepatocellular; Sarcoma, Clear Cell; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Brain metastases; Lymphoma; Leukemia, Myeloid, Acute; Sarcoma, Alveolar Soft Part; Glioma; Carcinoma, Squamous Cell; Pain; Adrenal Cortex Neoplasms; Pancreatic neuroendocrine tumors (pNET); Glioblastoma; Kidney Diseases; Hepatoblastoma; Pheochromocytoma; Carcinoma, Renal Cell; Rejection of liver transplantation; Carcinoid | Details |
Apatinib Mesylate | YN-968D1 | Approved | Advenchen Laboratories Llc | 艾坦, Aitan | Mainland China | Stomach Neoplasms | Jiangsu shengdi Medicine Co Ltd | 2014-10-17 | Carcinoma, Adenoid Cystic; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Liver Diseases; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Nasopharyngeal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms; Solid tumours; Head and Neck Neoplasms | Details |
Tivozanib | AV-951; KRN-951; ASP-4130; Kil-8951 | Approved | Kyowa Hakko Kirin Co Ltd | Fotivda | EU | Carcinoma, Renal Cell | Recordati Netherlands BV | 2017-08-24 | Sarcoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Biliary Tract Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Solid tumours | Details |
Vorolanib | X-82; EYP-1901; CM-082 | Approved | Tyrogenex Inc | 伏美纳 | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Diabetic macular oedema; Diabetic Retinopathy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Macular Degeneration; Choroidal Neovascularization; Adenocarcinoma; Leukemia, Myeloid, Acute; Retinal Degeneration; Eye Diseases; Solid tumours; Wet Macular Degeneration; Retinal Diseases; Small Cell Lung Carcinoma; Neoplasms; Pancreatic Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Kidney Neoplasms | Details |
Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Glioma; Bile Duct Diseases; Peritoneal Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Sarcoma, Alveolar Soft Part; Fallopian Tube Neoplasms; Nasopharyngeal Carcinoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Osteoma; Melanoma; Neoplasms; Ovarian Neoplasms; Drug-Related Side Effects and Adverse Reactions; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Leiomyosarcoma; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Lung Diseases, Interstitial; Neuroendocrine Tumors; Liver Diseases; Sarcoma; Medullary thyroid cancer (MTC) | Details |
Axitinib | PF-01367866; AG-13736; AG-013736 | Approved | Pfizer Pharmaceuticals Ltd (China) | 英立达, Inlyta | United States | Carcinoma, Renal Cell | Pf Prism Cv | 2012-01-27 | Lung Neoplasms; Carcinoma, Adenoid Cystic; Mesothelioma; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Sarcoma; Colorectal Neoplasms; Hepatic Insufficiency; Lymphoma; Neuroendocrine Tumors; Carcinoma, Pancreatic Ductal; Thyroid Neoplasms; Leukemia, Myeloid, Acute; Paraganglioma; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Neoplasms; Ovarian Neoplasms; Solid tumours; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma; Kidney Neoplasms; Glioblastoma; Adrenal Cortex Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Skin Neoplasms; Nasopharyngeal Neoplasms; Carcinoma, Ductal; Prostatic Neoplasms, Castration-Resistant | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Carcinoma, Squamous Cell; Sarcoma; Prostatic Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Peritoneal Neoplasms; Astrocytoma; Genital Neoplasms, Female; Hepatic Insufficiency; Silicosis; Gliosarcoma; Breast Neoplasms; Lung Neoplasms; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Adenocarcinoma; Glioblastoma; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoma, Renal Cell; Carcinoid Tumor; Endometrial Stromal Tumors; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Ovarian Neoplasms; Scleroderma, Systemic; Neoplasms; Small Cell Lung Carcinoma; Lung Diseases, Interstitial; Mesothelioma; Pulmonary Fibrosis; Multiple Myeloma; Asbestosis; Oligodendroglioma; Neuroendocrine Tumors | Details |
Vandetanib | AZD-6474; CH-331; ZD-6474 | Approved | Astrazeneca Pharmaceutical Co Ltd | Zactima, Caprelsa | United States | Carcinoma, Neuroendocrine; Thyroid Neoplasms | Genzyme Corp | 2011-04-06 | Lung Neoplasms; Neuroblastoma; Medullary thyroid cancer (MTC); Prostatic Neoplasms; Urethral Neoplasms; Peritoneal Neoplasms; Gliosarcoma; Colorectal Neoplasms; Ureteral Neoplasms; Gastrointestinal Stromal Tumors; Diffuse Intrinsic Pontine Glioma; Lymphoproliferative Disorders; Astrocytoma; Thyroid Neoplasms; Pleural Effusion; Carcinoma, Squamous Cell; Lymphoma; Fallopian Tube Neoplasms; Multiple Endocrine Neoplasia Type 2b; Glioma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Precancerous Conditions; Neoplasm Metastasis; Adenocarcinoma; von Hippel-Lindau Disease; Carcinoma, Hepatocellular; Anus Neoplasms; Biliary Tract Neoplasms; Solid tumours; Kidney Neoplasms; Intestinal Neoplasms; Ovarian Neoplasms; Pheochromocytoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Abdominal Neoplasms; Head and Neck Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Colonic Neoplasms; S | Details |
Ramucirumab | IMC-1121; IMC-1C11; LY-3009806; IMC-1121-B; BLA-125477 | Approved | Dyax Pharma | Cyramza | United States | Gastrointestinal Stromal Tumors | Eli Lilly And Company | 2014-04-21 | Breast Neoplasms; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Ureteral Neoplasms; Urologic Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Esophageal Neoplasms; Carcinoid Tumor; Stomach Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Solid tumours | Details |
Fruquintinib | HMPL-013; TAK-113 | Approved | Hutchison Medipharma Ltd | 爱优特, Elunate, FRUZAQLA | Mainland China | Colorectal Neoplasms | Hutchison Medipharma Ltd | 2018-09-04 | Kidney Diseases; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Breast Neoplasms; Sarcoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Solid tumours; Colonic Neoplasms; Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Biliary Tract Neoplasms | Details |
Ripretinib | DCC-2618 | Approved | Deciphera | Qinlock, 擎乐 | United States | Gastrointestinal Stromal Tumors | Deciphera Pharmaceuticals Llc | 2020-05-15 | Neoplasms; Mastocytosis, Systemic; Gastrointestinal Stromal Tumors | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Esophageal adenocarcinoma; Osteosarcoma; Sarcoma, Ewing; Bile Duct Neoplasms; Peritoneal Neoplasms; Bone Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Fallopian Tube Neoplasms; Lung Neoplasms; Thyroid Neoplasms; Sarcoma; Leukemia, Myeloid, Acute; Thymoma; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Somatostatinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Solid tumours; Liver Neoplasms; Carcinoid Tumor; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Islet Cell; Insulinoma; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Glucagonoma; Carcinoma, Adenoid Cystic; Adenoma; Gastrinoma | Details |
Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Uterine Cervical Diseases; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Neoplasms; Choriocarcinoma; Lymphoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Mucoepidermoid; Gliosarcoma; Genital Neoplasms, Female; Leukemia, Myeloid, Acute; Peritoneal Neoplasms; Brain Neoplasms; Urethral Neoplasms; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Prostatic Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma; Breast Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Neoplasm Metastasis; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Gastrointestinal Neoplasms; Paraganglioma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Melanoma; Gastrinoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Embryonal; Germinoma; Glioma; Carcinoma, Neuroendocrine; Epistaxis; Carcinoma, Ovarian Epithelial; Neoplasms; Squamous Cell Carcinoma of Head a | Details |
Lenvatinib Mesylate | ER-203492-00; E-7080; MK-7902 | Approved | Eisai Co Ltd | Lenvima, Lenvima/Kisplyx, 乐卫玛, Kisplyx | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Carcinoma, Adenoid Cystic; Thyroid Cancer, Papillary; Melanoma; Paraganglioma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Thyroid Neoplasms; Endometrial Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Breast Neoplasms; Osteosarcoma; Solid tumours; Adenocarcinoma, Follicular; Liver Diseases; Neuroendocrine Tumors; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Adenocarcinoma of Lung; Neoplasms; Esophageal Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Pheochromocytoma; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Leiomyosarcoma; Solid tumours; Recurrence; Ovarian Neoplasms; Leukemia, Erythroblastic, Acute; Rhabdomyosarcoma; Leukemia, Myelogenous, Chronic; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Fibromatosis, Aggressive; Kidney Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid; Carcinoma, Renal Cell; Histiocytoma, Malignant Fibrous; Carcinoma; Hemangiosarcoma; Carcinoid Tumor; Stomach Neoplasms; Insulinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Islet Cell; Esophageal Neoplasms; Rectal Neoplasms; Vipoma; Myelodysplastic Syndromes; Neoplasms; Wilms Tumor; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Small Cell Lung Carcinoma; Lymphoma, Large-Cell, Immunoblastic; Salivary Gland Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Multiple Endocrine Neoplasia Type 2a; Glioblastoma; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Colonic Neoplasms; Leukemia, Myelomonocytic, Ch | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Kanitinib | CX-1003 | Phase 1 Clinical | Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd | Solid tumours | Details |
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lung Neoplasms | Details |
Cediranib | AZD2171; AZD-2171; NSC-732208 | Phase 3 Clinical | Astrazeneca Plc | Ovarian Neoplasms; Ependymoma; Lymphoma, T-Cell, Peripheral; Medulloblastoma; Leiomyosarcoma; Biliary Tract Neoplasms; Head and Neck Neoplasms; Leukemia; Solid tumours; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Carcinoma, Renal Cell; Carcinoma; Rhabdoid Tumor; Leukemia, Hairy Cell; Spinal Cord Neoplasms; Stomach Neoplasms; Cystadenocarcinoma, Serous; Cystadenocarcinoma, Mucinous; Cystadenoma, Serous; Lymphoma, Large-Cell, Immunoblastic; Myelodysplastic Syndromes; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Neoplasms; Nasopharyngeal Neoplasms; Colonic Neoplasms; Glioblastoma; Pancreatic Neoplasms; Carcinoma, Verrucous; Leukemia-Lymphoma, Adult T-Cell; Hypopharyngeal Neoplasms; Hodgkin Disease; Triple Negative Breast Neoplasms; Salivary Gland Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Oligodendroglioma; Uveal melanoma; Prostatic Neoplasms, Castration-Res | Details |
Axitinib Implant(Aerie) | AR-14034 SR; AR-14034 | Phase 2 Clinical | Aerie Pharmaceuticals Inc | Macular Degeneration | Details |
VEGFR-1/2 peptide vaccine (Keio University) | Phase 2 Clinical | Keio University | Neurofibromatoses; Brain Neoplasms; Glioma | Details | |
Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
Glesatinib | MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265 | Phase 2 Clinical | Mirati Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
Multiple HLA-A2402 restricted epitope peptide vaccine (University of Tokyo/OncoTherapy Science) | Phase 2 Clinical | Oncotherapy Science, Inc, University Of Tokyo | Carcinoma, Non-Small-Cell Lung | Details | |
BR-55 | BR-55; BR55 CEUS | Phase 2 Clinical | Sonus Pharmaceuticals Ltd | Ovarian Neoplasms; Neoplasms; Contrast agents; Diagnostic agents; Inflammation | Details |
Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd | Neoplasms | Details |
JY-025 | JY-025 | Phase 3 Clinical | Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Pamufetinib | TAS-115 | Phase 1 Clinical | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | Neoplasms | Details |
Axitinib injectable suspension (Clearside Biomedical) | CLS-1002; CLS-011-A; CLS011A; CLS-AX | Phase 2 Clinical | Clearside Biomedical Inc | Macular Degeneration | Details |
Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 3 Clinical | Advenchen Laboratories Nanjing Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Metatinib Trometamol | BMS-817378; SIM-817378 | Phase 1 Clinical | Bristol-Myers Squibb Company | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms | Details |
Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) | Phase 1 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
Olinvacimab | SSS-23; TTAC-0001 | Phase 2 Clinical | Pharmabcine | Neoplasms; Glioblastoma; Triple Negative Breast Neoplasms; Neoplasm Metastasis | Details |
PZ-1 | PZ-1 | Phase 1 Clinical | Chongqing University Of Arts And Sciences | Solid tumours | Details |
Nintedanib Solution for Inhalation | AP02; AP-02 | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis | Details |
Simmitinib hydrochloride | SOMCL-15-290 | Phase 2 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Solid tumours | Details |
Gentuximab | Phase 3 Clinical | Genescience Pharmaceuticals Co Ltd | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details | |
KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Digestive System Neoplasms; Sarcoma, Ewing; Thymus Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Neoplasm Metastasis | Details |
PAN-90806 | CP-632; OSI-632; CP-547632; PAN-90806 | Phase 2 Clinical | Pfizer Inc, Osi Pharmaceutical | Ovarian Neoplasms; Abdominal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Macular Degeneration; Diabetic Retinopathy | Details |
LMV-12(HE003) | LMV-12(HE003) | Phase 1 Clinical | Nanchang Hongyi Technology Co Ltd | Solid tumours | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Recombinant anti-VEGFR2 chimeric monoclonaly antibody (GeneScience) | Phase 3 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
Zanzalintinib | XL-092 | Phase 3 Clinical | Exelixis Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Sitravatinib | MG-91516; MGCD-516; IND-155305; MG-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Mouth Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Ureteral Neoplasms; Hepatic Insufficiency; Solid tumours; Liposarcoma; Uveal melanoma; Lung Diseases; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Kidney Neoplasms | Details |
VEGFR2 peptide vaccine (VAXIMM) | VXM-01 | Phase 2 Clinical | Merck Serono | Glioblastoma; Pancreatic Neoplasms; Colorectal Neoplasms | Details |
KDR2-2 | Phase 2 Clinical | Guangzhou Huiborui Biomedical Technology Co Ltd | Neovascularization, Pathologic; Glaucoma, Neovascular; Corneal Neovascularization | Details | |
Brivanib Alaninate | ZL-2301; BMS-540215; BMS-582664 | Phase 2 Clinical | Bristol-Myers Squibb Company | Carcinoma, Squamous Cell; Carcinoma, Endometrioid; Adenocarcinoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Endometrial Neoplasms; Liver Neoplasms; Colorectal Neoplasms; Sarcoma; Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Rectal Neoplasms; Solid tumours | Details |
CEP-11981 | ESK-981; CEP-11981; SSR-106462; BOL-303213X | Phase 2 Clinical | Sanofi | Neoplasms; Adenoma, Islet Cell; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms | Details |
Pulocimab | AK-109 | Phase 2 Clinical | Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma | Details |
Ramucirumab biosimilar (CTTQ) | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
Axitinib intravitreal implant (Ocular Therapeutix) | OTX-TKI | Phase 1 Clinical | Ocular Therapeutix Inc | Macular Degeneration; Diabetic Retinopathy | Details |
Recombinant human anti-VEGFR2 monoclonal antibody (Buchang Pharma) | BC-001; BC001 | Phase 3 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Solid tumours; Esophageal Neoplasms; Colorectal Neoplasms | Details |
Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
ODM-203 | ODM-203 | Phase 1 Clinical | Orion Corp | Solid tumours | Details |
Ramucirumab biosimilar (Henlius) | HLX-12 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
MSB-0254 | MSB-0254 | Phase 1 Clinical | Mabspace Biomedicine (Suzhou) Co Ltd | Solid tumours | Details |
Gersizangitide | AXT-107 | Phase 2 Clinical | AsclepiX Therapeutics Inc | Diabetic macular oedema; Macular Degeneration | Details |
Sorafenib/MG-005 | MG-D-1509; MGD-1509 | Tri-Service General Hospital, Metagone Biotech Inc | Details | ||
FNX-006 | FNX-006 | Phase 1 Clinical | Sichuan University, Chengdu Fannuoxi Biomedical Technology Co Ltd | Triple Negative Breast Neoplasms; Melanoma | Details |
Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
SYHA-1817 | SYHA-1817 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell | Details |
EDP317 | ACTB-1003; EOC-317; EDP-317 | Phase 1 Clinical | Bayer AG, Act Biotech Inc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms | Details |
VEGFR2 peptide vaccine (Tokyo University) | Phase 1 Clinical | University Of Tokyo | Pancreatic Neoplasms | Details | |
AVI-3207 | AVI-3207 | Phase 1 Clinical | Avixgen | Macular Degeneration | Details |
Ilorasertib | ABT-348; A-9686600; Abbott-968660 | Phase 1 Clinical | Abbvie Inc | Leukemia, Myelogenous, Chronic; Solid tumours; Myelodysplastic Syndromes; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
RA1115-B1 | RA1115-B1 | Phase 1 Clinical | Suzhou Raymon Pharmaceuticals Co Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
LM-061 | LM-061 | Phase 1 Clinical | Shanghai Lixin Pharmaceutical Research and Development Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.